Elusys Therapeutics

Last updated
Elusys Therapeutics
Company type Private company
Founded1998
Headquarters Pine Brook, New Jersey
Key people
Dr. Elizabeth G. Posillico (Chief Executive Officer, President and Director)
Website elusys.com

Elusys Therapeutics is a biopharmaceutical company founded in Pine Brook, New Jersey in 1998. The company specializes in the development of antibodies for the treatment infectious diseases. [1] The antibodies are developed from protein complexes called heteropolymers which can bind to specific pathogens on one side and red blood cells on the other side.

Contents

The pathogens will be dragged to the liver where they will be destroyed. [2] The antibodies have a potential to be used for the treatments of many blood-borne diseases. Currently, the company focuses on the late-stage clinical trials of Anthim (Obiltoxaximab) to be used for treatment and prevention of inhaled anthrax. [3]

History

Ronald P. Taylor, a professor of biochemistry and molecular genetics at the University of Virginia developed protein complexes called heteropolymers that mimic the natural process of white and red blood cells in clearing out the disease off the bloodstream.

The heteropolymers have specific binding that can bind to specific pathogens on one side and red blood cells on the other side. The red blood cells with the attached pathogens are delivered to the liver to be destroyed. In animal testing, the method can clear out pathogens within 2 hours.

Taylor's research were partially funded by the National Institutes of Health and the Defense Advanced Research Projects Agency [2] [4] Additional funding was arranged by Seed-One Ventures, a venture capital company, through the formation of Elusys Therapeutics to raise several million dollars. Jeff Wolf, the founding CEO Elusys and Managing Partner of Seed-One, selected Stephen Sudovar as the CEO of Elusys. Sudovar was the former President of Roche Laboratories a division of Hoffmann-La Roche. Wolf also arranged to have Elusys' board of directors made up of people with prior experience from top global pharmaceutical companies and Food and Drug Administration (FDA). [5] As a startup, the company tested its first heteropolymers by using two chemically linked monoclonal antibodies for the treatment of lupus. [6]

Elusys is a member of the Alliance for Biosecurity. [7] The alliance is a group of companies and scholars that work to promote the development of vaccines and other measures that can be used in the case of a pandemic or bioterrorism attack. [8] [9]

Treatment

Anthim is monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).

Elusys initially collaborated with University of Texas at Austin and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in the development of Anthim. [6] With the bioterrorism risk of anthrax, the United States Department of Health and Human Services awarded a five-year contract in 2010 valued at $143 million to develop IV-based drug to treat patients who are already infected by anthrax. In 2011, the company was awarded with an additional five-year contract valued at $68.9 million to develop intramuscular injection for anthrax prevention measure. [10] In 2012, the company was awarded additional $50.2 million to test the efficacy of the treatment. [11]

The Biologics License Application for both intravenous and intramuscular administrations was accepted by the FDA in June 2015 with efficacy data of animal models and safety data from human volunteers. [12] In March 2016, Anthim was approved to treat inhalational anthrax in conjunction with appropriate antibacterial drugs, also for prevention when alternative therapies are not available or appropriate. [13]

In November 2015, the company received a five-year contract of $44.9 million for the production and future delivery of Anthim to the Strategic National Stockpile. [14]

Related Research Articles

Biodefense refers to measures to restore biosecurity to a group of organisms who are, or may be, subject to biological threats or infectious diseases. Biodefense is frequently discussed in the context of biowar or bioterrorism, and is generally considered a military or emergency response term.

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">Rituximab</span> Biopharmaceutical drug

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza, Rixathon, Ruxience, and Truxima.

Hubert Jacob Paul Schoemaker was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development of stem-cell therapies.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.

Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

<span class="mw-page-title-main">CD33</span> Mammalian protein found in Homo sapiens

CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells.

<span class="mw-page-title-main">Biomedical Advanced Research and Development Authority</span> Government organization in Washington D.C., United States

The Biomedical Advanced Research and Development Authority (BARDA)' is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.

Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.

Biosecurity in the United States is governed by the Bureau of Western Hemisphere Affairs, which is part of the US Department of State. It obtains guidance and advice on specific matters relating to biosecurity from various other government agencies.

<span class="mw-page-title-main">Anthrax vaccine adsorbed</span> Vaccine

Anthrax vaccine adsorbed, sold under the brand name Biothrax among others, is a vaccine intended to provide acquired immunity against Bacillus anthracis.

<span class="mw-page-title-main">Ebola virus disease treatment research</span>

There is a cure for the Ebola virus disease that is currently approved for market the US government has inventory in the Strategic National Stockpile. For past and current Ebola epidemics, treatment has been primarily supportive in nature.

Dinutuximab and dinutuximab beta are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.

Obiltoxaximab, sold under the brand name Anthim among others, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores.

<span class="mw-page-title-main">Alliance for Biosecurity</span>

The Alliance for Biosecurity is a consortium of companies that develop products to respond to national security threats, including bioterrorism pathogens and emerging infectious diseases. It is headquartered in Washington DC.

Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.

Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus. It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.

Passive antibody therapy, also called serum therapy, is a subtype of passive immunotherapy that administers antibodies to target and kill pathogens or cancer cells. It is designed to draw support from foreign antibodies that are donated from a person, extracted from animals, or made in the laboratory to elicit an immune response instead of relying on the innate immune system to fight disease. It has a long history from the 18th century for treating infectious diseases and is now a common cancer treatment. The mechanism of actions include: antagonistic and agonistic reaction, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

Jennifer Maynard is an American chemist who is the Henry Beckman Professor in Chemical Engineering at the University of Texas at Austin. Her research considers the development of therapeutic targets for infectious diseases. She was elected a Senior Member of the National Academy of Inventors in 2023.

References

  1. ↑ "Company Overview of Elusys Therapeutics, Inc". Bloomberg Business. Retrieved 28 November 2015.
  2. 1 2 Sinha, Gunjan (February 2001). "Kicking out killers". Popular Science. 258 (2): 39. ISSN   0161-7370 . Retrieved 28 November 2015.
  3. ↑ "Elusys Therapeutics Inc. Company Information". Hoover's. Retrieved 28 November 2015.
  4. ↑ "Biochemist Ron Taylor Named Inventor Of The Year". University of Virginia News. 3 May 2000. Retrieved 28 November 2015.
  5. ↑ Baard, Erik (29 August 2000). "Inventing millionaires". The Village Voice. Retrieved 28 November 2015.
  6. 1 2 Brower, Vicki (1 March 2003). "Biotechnology to fight bioterrorism". EMBO Reports. 4 (3): 227–229. doi:10.1038/sj.embor.embor783. PMC   1315911 . PMID   12634833.
  7. ↑ "Our Members". Alliance for Biosecurity. Retrieved 2017-02-13.[ permanent dead link ]
  8. ↑ "Our Mission". Alliance for Biosecurity. Retrieved 2017-02-13.[ permanent dead link ]
  9. ↑ "Our Work". Alliance for Biosecurity. Archived from the original on 2017-02-14. Retrieved 2017-02-13.
  10. ↑ "Feds award Elusys $69 million to develop anthrax drug". NJBIZ. 12 September 2011. Retrieved 28 November 2015.
  11. ↑ Todd, Susan (2 August 2012). "Elusys forges ahead on anthrax treatment with $50.2 million in government funding". The Star-Ledger. Retrieved 28 November 2015.
  12. ↑ "FDA Accepts License Application For Anthrax Prevention Drug". Homeland Security Today. 1 June 2015. Retrieved 28 November 2015.[ permanent dead link ]
  13. ↑ News Release (21 March 2016). "FDA approves new treatment for inhalation anthrax". FDA.
  14. ↑ O'Brien, Kathleen (12 November 2015). "Anthrax drug wins $44.9 million contract for Morris firm". NJ.com. Retrieved 28 November 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.